Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gail J Roboz

Showing results (41-50 of 201) with videos related to

Pageof 21
Sort By:
Leukemia & Lymphoma|December 29, 2012
Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemiaEllen K Ritchie, Eric J Feldman, Paul J Christos, et al.
Leukemia & Lymphoma|February 28, 2020
Final safety and efficacy results from the CPX-351 early access program for older patients with high-risk or secondary acute myeloid leukemiaGail J Roboz, Melissa L Larson, S Eric Rubenstein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 24, 2014
Prevalence, management, and clinical consequences of QT interval prolongation during treatment with arsenic trioxideGail J Roboz, Ellen K Ritchie, Rebecca F Carlin, et al.
Clinical Epigenetics|July 24, 2019
Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemiaWoonbok Chung, Andrew D Kelly, Patricia Kropf, et al.
Cancer|August 9, 2020
Low participation rates and disparities in participation in interventional clinical trials for myelodysplastic syndromesCharlotte K Brierley, Emily C Zabor, Rami S Komrokji, et al.
Blood|November 26, 2008
A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical responseKeith W Pratz, Jorge Cortes, Gail J Roboz, et al.
Cancer|May 19, 2017
The effect of initial molecular profile on response to recombinant interferon-α (rIFNα) treatment in early myelofibrosisRichard T Silver, Ariella C Barel, Elena Lascu, et al.
Cancer|October 1, 2008
Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemiaGail J Roboz, Ellen K Ritchie, Tania Curcio, et al.
Nature Nanotechnology|March 27, 2019
FDA-approved ferumoxytol displays anti-leukaemia efficacy against cells with low ferroportin levelsVicenta Trujillo-Alonso, Edwin C Pratt, Hongliang Zong, et al.
Leukemia & Lymphoma|May 6, 2014
Phase I trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed acute leukemia or high-risk myelodysplastic syndromeGail J Roboz, H Jean Khoury, Elias Jabbour, et al.
Pageof 21

Showing results (41-50 of 201) with videos related to

Sort By:
Pageof 21
Leukemia & Lymphoma|December 29, 2012
Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemiaEllen K Ritchie, Eric J Feldman, Paul J Christos, et al.
Leukemia & Lymphoma|February 28, 2020
Final safety and efficacy results from the CPX-351 early access program for older patients with high-risk or secondary acute myeloid leukemiaGail J Roboz, Melissa L Larson, S Eric Rubenstein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 24, 2014
Prevalence, management, and clinical consequences of QT interval prolongation during treatment with arsenic trioxideGail J Roboz, Ellen K Ritchie, Rebecca F Carlin, et al.
Clinical Epigenetics|July 24, 2019
Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemiaWoonbok Chung, Andrew D Kelly, Patricia Kropf, et al.
Cancer|August 9, 2020
Low participation rates and disparities in participation in interventional clinical trials for myelodysplastic syndromesCharlotte K Brierley, Emily C Zabor, Rami S Komrokji, et al.
Blood|November 26, 2008
A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical responseKeith W Pratz, Jorge Cortes, Gail J Roboz, et al.
Cancer|May 19, 2017
The effect of initial molecular profile on response to recombinant interferon-α (rIFNα) treatment in early myelofibrosisRichard T Silver, Ariella C Barel, Elena Lascu, et al.
Cancer|October 1, 2008
Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemiaGail J Roboz, Ellen K Ritchie, Tania Curcio, et al.
Nature Nanotechnology|March 27, 2019
FDA-approved ferumoxytol displays anti-leukaemia efficacy against cells with low ferroportin levelsVicenta Trujillo-Alonso, Edwin C Pratt, Hongliang Zong, et al.
Leukemia & Lymphoma|May 6, 2014
Phase I trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed acute leukemia or high-risk myelodysplastic syndromeGail J Roboz, H Jean Khoury, Elias Jabbour, et al.
Pageof 21